Resultados de la búsqueda 311-320 of 2440 for mark bartlett
Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Giving venetoclax with ibrutinib and rituximab with ...
Data will contribute to creating treatment algorithms for symptom management for upper digestive diseases and for post-operative complications and symptoms as ...
Evaluate the influence of the critical shoulder angle (CSA) on rotator cuff failure after total anatomic shoulder arthroplasty. A Study to Develop Processes for ...
Most newly-diagnosed CLL patients have early-stage disease at the time of diagnosis and do not require treatment. Despite not needing therapy, these patients ...
The purpose of this study is to determine the impact of a recently developed artificial intelligence virtual assistant (AIVA) on plastic surgery patients ...
Almost one-half million people suffer venous thromboembolism annually in the United States, and one-third die from this disease.
The purpose of this study is to determine freedom from ipsilateral breast recurrence occurrences in patients receiving partial breast proton radiation therapy ...
Although survivorship recommendations have been developed in areas such as lymphoma and stem cell transplant, the long-term effects of CAR-T therapy are ...
All study subjects will receive acalabrutinib, durvalumab, and venetoclax. Acalabrutinib is FDA approved for treatment of chronic lymphocytic leukemia and small ...
Selumetinib is a drug that works by blocking some enzymes that low grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs ...
Mayo Clinic no respalda compañías ni productos. Las recaudaciones de los avisos comerciales financian nuestra misión sin fines de lucro.
Consulta estos éxitos de venta y ofertas especiales en libros y boletines informativos de Mayo Clinic Press.
¿Te gustaría hacer una donación deducible de impuestos y ser parte de una investigación de vanguardia y de una atención médica que transforma la medicina?